Abstract：
UNASSIGNED: An important respiratory pathogen that has led to multiple hospital outbreaks both inside and outside of the Arabian Peninsula is the Middle East Respiratory Syndrome Coronavirus (MERS-CoV). Given the elevated case fatality rate, there exists a pressing requirement for efficacious therapeutic agents.
UNASSIGNED: This is an updated review of the developments in MERS treatment approaches. Using databases like PubMed, Embase, Cochrane, Scopus, and Google Scholar, a thorough search was carried out utilizing keywords like \'MERS,\' \'MERS-CoV,\' and \'Middle East respiratory syndrome\' in conjunction with \'treatment\' or \'therapy\' from Jan 2012 to Feb 2024.
UNASSIGNED: MERS-CoV is a highly pathogenic respiratory infection that emerged in 2012 and continues to pose a significant public health threat. Despite ongoing efforts to control the spread of MERS-CoV, there is currently no specific antiviral treatment available. While many agents have been tested both in vivo and in vitro, none of them have been thoroughly examined in extensive clinical trials. Only case reports, case series, or cohort studies have been made available as clinical studies. However, there is a limited number of randomized-controlled trials. Because cases are irregular and sporadic, conducting a large prospective randomized trials for establishing an efficacious treatment might be difficult.
UNASSIGNED: This is an updated review of the developments in MERS treatment approaches. Using databases like PubMed, Embase, Cochrane, Scopus, and Google Scholar, a thorough search was carried out utilizing keywords like \'MERS,\' \'MERS-CoV,\' and \'Middle East respiratory syndrome\' in conjunction with \'treatment\' or \'therapy\' from Jan 2012 to Feb 2024.
UNASSIGNED: MERS-CoV is a highly pathogenic respiratory infection that emerged in 2012 and continues to pose a significant public health threat. Despite ongoing efforts to control the spread of MERS-CoV, there is currently no specific antiviral treatment available. While many agents have been tested both in vivo and in vitro, none of them have been thoroughly examined in extensive clinical trials. Only case reports, case series, or cohort studies have been made available as clinical studies. However, there is a limited number of randomized-controlled trials. Because cases are irregular and sporadic, conducting a large prospective randomized trials for establishing an efficacious treatment might be difficult.
摘要：
■导致阿拉伯半岛内外多次医院爆发的重要呼吸道病原体是中东呼吸综合征冠状病毒（MERS-CoV）。鉴于病死率上升，存在对有效治疗剂的迫切需求。
■这是对MERS治疗方法发展的最新回顾。使用像PubMed这样的数据库，Embase,科克伦,Scopus,和谷歌学者，利用像“MERS”这样的关键词进行了彻底的搜索，\'\'MERS-CoV,从2012年1月至2024年2月，\'和\'中东呼吸综合征\'与\'治疗\'或\'治疗\'结合。
■MERS-CoV是一种高致病性呼吸道感染，于2012年出现，并继续构成重大的公共卫生威胁。尽管一直在努力控制MERS-CoV的传播，目前没有特定的抗病毒治疗。虽然许多药物已经在体内和体外进行了测试，在广泛的临床试验中，它们都没有经过彻底的检查。只有病例报告,案例系列,或队列研究已作为临床研究提供。然而,随机对照试验数量有限.因为病例是不规则和零星的，进行大型前瞻性随机试验以确定有效的治疗方法可能很困难.
■这是对MERS治疗方法发展的最新回顾。使用像PubMed这样的数据库，Embase,科克伦,Scopus,和谷歌学者，利用像“MERS”这样的关键词进行了彻底的搜索，\'\'MERS-CoV,从2012年1月至2024年2月，\'和\'中东呼吸综合征\'与\'治疗\'或\'治疗\'结合。
■MERS-CoV是一种高致病性呼吸道感染，于2012年出现，并继续构成重大的公共卫生威胁。尽管一直在努力控制MERS-CoV的传播，目前没有特定的抗病毒治疗。虽然许多药物已经在体内和体外进行了测试，在广泛的临床试验中，它们都没有经过彻底的检查。只有病例报告,案例系列,或队列研究已作为临床研究提供。然而,随机对照试验数量有限.因为病例是不规则和零星的，进行大型前瞻性随机试验以确定有效的治疗方法可能很困难.
